References
- Janssen P, Niemegeers C, Awouters F, et al. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1988;244:685–693.
- Krishna S, Swapana B, Rakesh G, et al. Method development and validation for estimation of risperidone in novel liquisolid formulation by RP-HPLC. Der Pharmacia Lettre. 2014;6:166–174.
- Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004;70:91–100.
- Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–1132.
- Desai N, Huq Z, Martin S, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The schizophrenia treatment and assessment group. Adv Ther 1998;16:78–88.
- Association AP. American psychiatric association practice guidelines for the treatment of psychiatric disorders: compendium 2006. Arlington (VA): American Psychiatric Pub; 2006.
- Health NCCfM. 2009. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. London: National Institute for Clinical Excellence.
- Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics. Drugs 2003;63:493–512.
- Ramstack J, Grandolfi G, Mannaert E, et al. Risperdal Consta TM: prolonged-release injectable delivery of risperidone using Medisorb® microsphere technology. Abstr Am Assoc Pharm Sci 2002;4(S1).
- Su ZX, Shi YN, Teng LS, et al. Biodegradable poly (D, L-lactide-co-glycolide)(PLGA) microspheres for sustained release of risperidone: zero-order release formulation. Pharm Dev Technol 2011;16:377–384.
- Sanka K, Bandari S, Jukanti R, Veerareddy PR. Colon-specific microparticles of piroxicam: Formulation and optimization using 32 factorial design. J Dispersion Sci Technol 2011;32:1396–1403.
- Sanka K, Pragada RR, Veerareddy PR. A pH-triggered delayed-release chronotherapeutic drug delivery system of aceclofenac for effective management of early morning symptoms of rheumatoid arthritis. J Microencapsul 2015;32:794–803.
- Rong X, Mo X, Ren T, et al. Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. Eur J Pharm Sci 2011;43:334–342.
- Samimi R, Salarian M, Xu WZ, et al. Encapsulation of acetyl ginsenoside Rb1 within monodisperse poly (dl-lactide-co-glycolide) microspheres using a microfluidic device. Ind Eng Chem Res 2014;53:11333–11344.
- Xu Q, Hashimoto M, Dang TT, et al. Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow‐focusing device for controlled drug delivery. Small 2009;5:1575–1581.
- Yuan W, Zhang Y, Wu F, et al. Preparation of protein-loaded sustained-release microspheres via ‘solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/hO/E)’emulsification. Colloids Surf B Biointerfaces 2010;79:326–333.
- D’Souza S, Faraj JA, Giovagnoli S, DeLuca PP. Development of risperidone PLGA microspheres. J Drug Deliv 2014;2014:620464.
- DeLuca PP, Mehta RC, Hausberger AG, Thanoo B. Biodegradable polyesters for drug and polypeptide delivery. Proceedings of the ACS Symposium Series 520. Washington, DC: American Chemical Society; 1993.
- Edlund U, Albertsson AC. Degradable polymer microspheres for controlled drug delivery. In: Albertsson AC, ed. Degradable aliphatic polyesters. Berlin Heidelberg:Springer; 2002; 67–112.
- Xie CL, Wang WW, Zhang SF, et al. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep 2014;4:7506. doi: 10.1038/srep07506.
- Kim KK, Pack DW. Microspheres for drug delivery. BioMEMS and biomedical nanotechnology. Berlin Heidelberg: Springer; 2006:19–50.
- Schneider T, Zhao H, Jackson JK, et al. Use of hydrodynamic flow focusing for the generation of biodegradable camptothecin‐loaded polymer microspheres. J Pharm Sci 2008;97:4943–4954.
- Ganapathy H, Al-Hajri E, Ohadi M. Mass transfer characteristics of gas–liquid absorption during Taylor flow in mini/microchannel reactors. Chem Eng Sci 2013;101:69–80.
- Lan W, Li S, Wang Y, Luo G. CFD simulation of droplet formation in microchannels by a modified level set method. Ind Eng Chem Res 2014;53:4913–4921.
- Qian D, Lawal A. Numerical study on gas and liquid slugs for Taylor flow in a T-junction microchannel. Chem Eng Sci 2006;61:7609–7625.
- Shao N, Gavriilidis A, Angeli P. Mass transfer during Taylor flow in microchannels with and without chemical reaction. Chem Eng J 2010;160:873–881.
- Rahimi M, Hajialyani M, Beigzadeh R, Alsairafi AA. Application of artificial neural network and genetic algorithm approaches for prediction of flow characteristic in serpentine microchannels. Chem Eng Res Des 2015;98:147–156.
- Thome J, Bar-Cohen A, Revellin R, Zun I. Unified mechanistic multiscale mapping of two-phase flow patterns in microchannels. Exp Therm Fluid Sci 2013;44:1–22.
- Zhang T, Cao B, Fan Y, et al. Gas–liquid flow in circular microchannel. Part I: Influence of liquid physical properties and channel diameter on flow patterns. Chem Eng Sci 2011;66:5791–5803.
- Su Z, Sun F, Shi Y, et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly (D, L-lactide-co-glycolide) microsphere. Chem Pharm Bull 2009;57:1251–1256.
- Hu Z, Liu Y, Yuan W, et al. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloids Surf B Biointerfaces 2011;86:206–211.